mTOR 与癌症：一条通路上的多个环。
mTOR and cancer: many loops in one pathway.
机构信息
Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02142, United States.
出版信息
Curr Opin Cell Biol. 2010 Apr;22(2):169-76. doi: 10.1016/j.ceb.2009.10.007. Epub 2009 Nov 27.
Abstract
The mammalian target of rapamycin (mTOR) is a master regulator of cell growth and division that responds to a variety of stimuli, including nutrient, energy, and growth factors. In the last years, a significant number of pieces have been added to the puzzle of how mTOR coordinates and executes its functions. Extensive research on mTOR has also uncovered a complex network of regulatory loops that impact the therapeutic approaches aimed at targeting mTOR.
摘要
哺乳动物雷帕霉素靶蛋白（mTOR）是细胞生长和分裂的主要调节因子，对各种刺激（包括营养、能量和生长因子）作出反应。在过去几年中，人们对 mTOR 如何协调和执行其功能有了更多的了解。对 mTOR 的广泛研究还揭示了一个复杂的调节环网络，这些调节环网络影响着靶向 mTOR 的治疗方法。
相似文献
1
mTOR and cancer: many loops in one pathway.
Curr Opin Cell Biol. 2010 Apr;22(2):169-76. doi: 10.1016/j.ceb.2009.10.007. Epub 2009 Nov 27.
2
Dissecting the role of mTOR: lessons from mTOR inhibitors.
Biochim Biophys Acta. 2010 Mar;1804(3):433-9. doi: 10.1016/j.bbapap.2009.12.001. Epub 2009 Dec 11.
3
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121.
4
Functional consequences of mTOR inhibition.
Curr Opin Drug Discov Devel. 2010 Jan;13(1):31-40.
5
Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells.
Oncotarget. 2014 Sep 30;5(18):8442-51. doi: 10.18632/oncotarget.2319.
6
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.
Acta Physiol (Oxf). 2009 May;196(1):65-80. doi: 10.1111/j.1748-1716.2009.01972.x. Epub 2009 Feb 19.
7
[mTOR and non-small cell lung cancer].
Zhongguo Fei Ai Za Zhi. 2010 Jan;13(1):69-72. doi: 10.3779/j.issn.1009-3419.2010.01.13.
8
The potential role of mTOR inhibitors in the treatment of endocrine tumors.
J Endocrinol Invest. 2010 Apr;33(4):276-81. doi: 10.1007/BF03345792. Epub 2010 May 5.
9
Targeting mTOR globally in cancer: thinking beyond rapamycin.
Cell Cycle. 2009 Dec;8(23):3831-7. doi: 10.4161/cc.8.23.10070. Epub 2009 Dec 14.
10
Rapamycin: the cure for all that ails.
J Mol Cell Biol. 2010 Feb;2(1):17-9. doi: 10.1093/jmcb/mjp033. Epub 2009 Oct 4.
引用本文的文献
1
Dose-dependent immunotoxic mechanisms of celastrol via modulation of the PI3K-Akt signaling pathway.
Front Pharmacol. 2025 May 27;16:1567193. doi: 10.3389/fphar.2025.1567193. eCollection 2025.
2
Identification of biomarkers and potential drug targets in DFU based on fundamental experiments and multi-omics joint analysis.
Front Pharmacol. 2025 May 23;16:1561179. doi: 10.3389/fphar.2025.1561179. eCollection 2025.
3
Protein Kinases as Mediators for miRNA Modulation of Neuropathic Pain.
Cells. 2025 Apr 11;14(8):577. doi: 10.3390/cells14080577.
4
Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast Cancer.
Int J Mol Sci. 2025 Apr 7;26(7):3438. doi: 10.3390/ijms26073438.
5
Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment.
PLoS One. 2025 Feb 7;20(2):e0315171. doi: 10.1371/journal.pone.0315171. eCollection 2025.
6
JR-AB2-011 induces fast metabolic changes independent of mTOR complex 2 inhibition in human leukemia cells.
Pharmacol Rep. 2024 Dec;76(6):1390-1402. doi: 10.1007/s43440-024-00649-7. Epub 2024 Sep 11.
7
Charting cancer's course: revealing the role of diet, exercise, and the microbiome in cancer evolution and immunotherapy response.
Clin Transl Oncol. 2025 Feb;27(2):473-485. doi: 10.1007/s12094-024-03595-1. Epub 2024 Aug 2.
8
Comprehensive Review on Bimolecular Fluorescence Complementation and Its Application in Deciphering Protein-Protein Interactions in Cell Signaling Pathways.
Biomolecules. 2024 Jul 17;14(7):859. doi: 10.3390/biom14070859.
9
Regulation of mesenchymal stem cell differentiation by autophagy.
Open Med (Wars). 2024 May 21;19(1):20240968. doi: 10.1515/med-2024-0968. eCollection 2024.
10
A Novel Role for the Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Delta Isoform in Hepatocellular Proliferation.
Am J Pathol. 2024 Aug;194(8):1511-1527. doi: 10.1016/j.ajpath.2024.03.016. Epub 2024 May 3.
本文引用的文献
1
Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1.
Mol Cell Biol. 2009 Nov;29(21):5657-70. doi: 10.1128/MCB.00735-09. Epub 2009 Aug 31.
2
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Cancer Res. 2009 Aug 1;69(15):6232-40. doi: 10.1158/0008-5472.CAN-09-0299. Epub 2009 Jul 7.
3
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
Cancer Cell. 2009 Jul 7;16(1):21-32. doi: 10.1016/j.ccr.2009.04.012.
4
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.
Cell. 2009 May 29;137(5):873-86. doi: 10.1016/j.cell.2009.03.046. Epub 2009 May 14.
5
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).
Biochem J. 2009 Jun 12;421(1):29-42. doi: 10.1042/BJ20090489.
6
The pharmacology of mTOR inhibition.
Sci Signal. 2009 Apr 21;2(67):pe24. doi: 10.1126/scisignal.267pe24.
7
Molecular mechanisms of mTOR-mediated translational control.
Nat Rev Mol Cell Biol. 2009 May;10(5):307-18. doi: 10.1038/nrm2672. Epub 2009 Apr 2.
8
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
PLoS Biol. 2009 Feb 10;7(2):e38. doi: 10.1371/journal.pbio.1000038.
9
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
Curr Opin Cell Biol. 2009 Apr;21(2):194-8. doi: 10.1016/j.ceb.2008.12.011. Epub 2009 Feb 7.
10
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.
Cancer Cell. 2009 Feb 3;15(2):148-59. doi: 10.1016/j.ccr.2008.12.017.
Zotero 插件